Home Cart Sign in  
Chemical Structure| 1361951-15-6 Chemical Structure| 1361951-15-6

Structure of TP-3654
CAS No.: 1361951-15-6

Chemical Structure| 1361951-15-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TP-3654 is a selective Pim kinase inhibitor with Ki values of 5nM, 239nM and 42nM for Pim-1, Pim-2 and Pim-3, respectively, as well as with an average EC50 of 67nM for cellular PIM-1 inhibition in the PIM-1/BAD overexpression system and with moderate potency to FLT3.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of TP-3654

CAS No. :1361951-15-6
Formula : C22H25F3N4O
M.W : 418.46
SMILES Code : OC(C)([C@H]1CC[C@@H](CC1)NC2=NN3C(C=C2)=NC=C3C4=CC=CC(C(F)(F)F)=C4)C
MDL No. :MFCD28502206
InChI Key :XRNVABDYQLHODA-UHFFFAOYSA-N
Pubchem ID :66598080

Safety of TP-3654

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of TP-3654

epigenetics
JAK-STAT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
UM-UC-3 bladder cancer cells 3, 1, 0.3, 0.03 μM 12 hours To evaluate the effect of TP-3654 on phospho-BAD (S112) levels in UM-UC-3 cells, results showed that TP-3654 significantly reduced phospho-BAD levels. Neoplasia. 2014 May;16(5):403-12.
MOLM-14 cells 1 μmol/L 48 hours To evaluate the cytotoxicity and apoptosis induction effects of TP-3654 in combination with gilteritinib, results showed that the combination treatment significantly increased apoptosis induction. Cancer Res Commun. 2024 Feb 16;4(2):431-445.
MV4-11 cells 1 μmol/L 48 hours To evaluate the cytotoxicity and apoptosis induction effects of TP-3654 in combination with gilteritinib, results showed that the combination treatment significantly increased apoptosis induction. Cancer Res Commun. 2024 Feb 16;4(2):431-445.
Ba/F3-ITD cells 1 μmol/L 48 hours To evaluate the cytotoxicity and apoptosis induction effects of TP-3654 in combination with gilteritinib, results showed that the combination treatment significantly increased apoptosis induction. Cancer Res Commun. 2024 Feb 16;4(2):431-445.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Homozygous Jak2V617F knock-in mouse model Oral gavage 150 mg/kg Once daily for 6 weeks To evaluate the effect of TP-3654 on myelofibrosis; TP-3654 significantly reduced leukocytosis and splenomegaly and ameliorated bone marrow fibrosis Leukemia. 2022 Mar;36(3):746-759
Nu/Nu mice UM-UC-3 bladder cancer xenograft model Oral 200 mg/kg Once daily for 5 days, 2 days off, for 3 weeks To evaluate the effect of TP-3654 on UM-UC-3 xenograft tumor growth, results showed that TP-3654 significantly inhibited tumor growth. Neoplasia. 2014 May;16(5):403-12.
NRG mice MV4-11-luc cell xenograft model Oral gavage 50 mg/kg 5 days per week each week To evaluate the in vivo anti-leukemia efficacy of TP-3654 in combination with gilteritinib, results showed that the combination treatment significantly decreased leukemia burden and prolonged survival. Cancer Res Commun. 2024 Feb 16;4(2):431-445.

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03715504 Advanced Solid Tumors PHASE1 COMPLETED 2021-07-08 MD Anderson, Houston, Texas, 7... More >>7030, United States|Huntsman Cancer Institute, Salt Lake City, Utah, 84112, United States|University of Virginia, Charlottesville, Virginia, 22903, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.39mL

0.48mL

0.24mL

11.95mL

2.39mL

1.19mL

23.90mL

4.78mL

2.39mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories